Acinetobacter baumannii may exhibit phenotypic heterogeneous growth under exposure to antibiotics. We investigated the in vitro characteristics of A. baumannii isolates grown heterogeneously in the presence of meropenem and their virulence evaluated in experimental infections treated with meropenem. Five clinical A. baumannii isolates and the respective heterogeneously grown subpopulations were tested by agar dilution minimum inhibitory concentration (MIC) testing, pulsed field gel electrophoresis (PFGE), population analysis using meropenem and growth curves. The virulence of isolates and the therapeutic efficacy of three meropenem dosing schemes was evaluated in a neutropenic murine thigh infection model. The clinical isolates were meropenem-susceptible (MICs 1 to 4 mg/liter) and exhibited three distinct PFGE patterns. In all clinical isolates, population analysis yielded heterogeneously grown colonies. After seven subcultures in antibiotic-free media, resistant MIC levels were retained in two isolates (heteroresistant), while three isolates were reversed to susceptible MICs (persisters). Clinical isolates and heterogeneous subpopulations had similar growth rates. The heterogeneously grown A. baumannii subpopulations had reduced virulence, killing considerably fewer animals than the respective clinical isolates without treatment. The meropenem treatment outcome was similar in infections caused by the clinical and the heterogeneous isolates, irrespective to their MICs. In vitro meropenem exposure induces phenotypic heterogeneous growth in A. baumannii. Compared with the parental clinical isolates, the heterogeneously grown subpopulations exhibited lower virulence, killing fewer mice and responding equally to meropenem treatment, despite their higher MICs.
References
[1]
Fournier, P.E.; Richet, H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. 2006, 42, 692–699, doi:10.1086/500202.
[2]
Bonomo, R.A.; Szabo, D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 2006, 43, 49–56, doi:10.1086/504477.
[3]
Bogaerts, P.; Naas, T.; Wybo, I.; Bauraing, C.; Soetens, O.; Piérard, D.; Nordmann, P.; Glupczynski, Y. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. J. Clin. Microbiol. 2006, 44, 4189–4192, doi:10.1128/JCM.00796-06.
[4]
Tsakris, A.; Tsioni, C.; Pournaras, S.; Polyzos, S.; Maniatis, A.N.; Sofianou, D. Spread of low-level carbapenem-resistant Acinetobacter baumannii in a tertiary care Greek hospital. J. Antimicrob. Chemother. 2003, 52, 1046–1047, doi:10.1093/jac/dkg470.
[5]
Hawley, J.S.; Murray, C.K.; Jorgensen, J.H. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother. 2008, 52, 351–352, doi:10.1128/AAC.00766-07.
[6]
Lee, H.Y.; Chen, C.L.; Wang, S.B.; Su, L.H.; Chen, S.H.; Liu, S.Y.; Wu, T.L.; Lin, T.Y.; Chiu, C.H. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: Mechanism and clinical implications. Int. J. Antimicrob. Agents 2011, 37, 302–308, doi:10.1016/j.ijantimicag.2010.12.015.
[7]
Ikonomidis, A.; Neou, E.; Gogou, V.; Vrioni, G.; Tsakris, A.; Pournaras, S. Heteroresistance to meropenem in carbapenem-susceptible Acinetobacter baumannii. J. Clin. Microbiol. 2009, 47, 4055–4059.
[8]
Pournaras, S.; Ikonomidis, A.; Markogiannakis, A.; Maniatis, A.N.; Tsakris, A. Heteroresistance to carbapenems in Acinetobacter baumannii. J. Antimicrob. Chemother. 2005, 55, 1055–1056, doi:10.1093/jac/dki115.
Balaban, N.Q.; Merrin, J.; Chait, R.; Kowalik, L.; Leibler, S. Bacterial persistence as a phenotypic switch. Science 2004, 305, 1622–1625, doi:10.1126/science.1099390.
[11]
Ko, W.C.; Lee, H.C.; Chiang, S.R.; Yan, J.J.; Wu, J.J.; Lu, C.L.; Chuang, Y.C. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J. Antimicrob. Chemother. 2004, 53, 393–395, doi:10.1093/jac/dkh080.
[12]
Morinaga, Y.; Yanagihara, K.; Nakamura, S.; Yamamoto, K.; Izumikawa, K.; Seki, M.; Kakeya, H.; Yamamoto, Y.; Yamada, Y.; Kohno, S.; et al. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J. Antimicrob. Chemother. 2008, 62, 1326–1331, doi:10.1093/jac/dkn411.
[13]
Tam, V.H.; Ledesma, K.R.; Schilling, A.N.; Lim, T.P.; Yuan, Z.; Ghose, R.; Lewis, R.E. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn. Microbiol. Infect. Dis. 2009, 64, 427–433, doi:10.1016/j.diagmicrobio.2009.03.031.
[14]
Gaynes, R.; Edwards, J.R. National Nosocomial Infections Srveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005, 41, 848–854, doi:10.1086/432803.
[15]
Fernández Cuenca, F.; Sánchez Mdel, C.; Caballero-Moyano, F.J.; Vila, J.; Martínez-Martínez, L.; Bou, G.; Ba？o, J.R.; Pascual, A. Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in Acinetobacter. baumannii. Int. J. Antimicrob. Agents 2012, 39, 472–477, doi:10.1016/j.ijantimicag.2012.01.015.
[16]
Fernández-Reyes, M.; Rodríguez-Falcón, M.; Chiva, C.; Pachón, J.; Andreu, D.; Rivas, L. The cost of resistance to colistin in Acinetobacter baumannii: Proteomic perspective. Proteomics 2009, 9, 1632–1645, doi:10.1002/pmic.200800434.
[17]
Guo, B.; Abdelraouf, K.; Ledesma, K.R.; Nikolaou, M.; Tam, V.H. Predicting bacterial fitness cost associated with drug resistance. J. Antimicrob. Chemother. 2012, 67, 928–932, doi:10.1093/jac/dkr560.
[18]
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Seventeenth Informational Supplement. Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2007; p. M100-S17.
[19]
Tenover, F.C.; Arbeit, R.D.; Goering, R.V.; Mickelsen, P.A.; Murray, B.E.; Persing, D.H.; Swaminathan, B.; Arbeit, R.D. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Microbiol. 1995, 33, 2233–2239.
[20]
Pournaras, S.; Markogiannakis, A.; Ikonomidis, A.; Kondyli, L.; Bethimouti, K.; Maniatis, A.N.; Legakis, N.J.; Tsakris, A. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J. Antimicrob. Chemother. 2006, 57, 557–561, doi:10.1093/jac/dkl004.
[21]
Lee, K.; Yum, J.H.; Yong, D.; Lee, H.M.; Kim, H.D.; Docquier, J.D.; Rossolini, G.M.; Chong, Y. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother. 2005, 49, 4485–4491, doi:10.1128/AAC.49.11.4485-4491.2005.
[22]
Oh, E.J.; Lee, S.; Park, Y.J.; Park, J.J.; Park, K.; Kim, S.I.; Kang, M.W.; Kim, B.K. Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter. baumannii in a Korean university hospital and comparison of screening methods for detecting metallo-β-lactamase. J. Microbiol. Methods 2003, 54, 411–418, doi:10.1016/S0167-7012(03)00090-3.
[23]
Hegde, S.S.; Reyes, N.; Skinner, R.; Difuntorum, S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J. Antimicrob. Chemother. 2008, 61, 169–172.
[24]
Andes, D.; Craig, W.A. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob. Agents Chemother. 1998, 42, 2375–2379.
[25]
Dudhani, R.V.; Turnidge, J.D.; Nation, R.L.; Li, J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 2010, 65, 1984–1990, doi:10.1093/jac/dkq226.
